Super happy to share this interesting paper led by J. Fournier with a super team: L. Barret, C. Khouri, (me), Boussageon Rémy and M. Roustit: "The evidence base of the ten most prescribed drugs in England, France and the United States" in Journal of Clinical Epidemiology. A 🧶 jclinepi.com/article/S0895-…

I’m not sure if this is such a positive message, correlates well with the modest efficacy of esketamine unless the point is that no matter how bad the studies or resulta at some point the FDA will have to approve it.

Do I have any Flemish speaking friend/follower who could do me a small favor? Helping me navigate a website in Flemish. PM for details

Expectancy goes a long way (but very nice design)

Does Ozempic increase the risk of suicidal thoughts? A new Georgios Schoretsanitis et al study muddles the picture about GLP-1 drugs and adverse events statnews.com/2024/08/20/glp… via Elaine Chen Robin Conibere Samei Huda Dr K Wildschut OLD AGE Psychiatrist 🤾🏽‍♂️ Dr Sanil Rege FRANZCP | MRCPsych Jesse Luke💊🧠

I like to think I am difficult to surprise but rectal ketamine passed that bar.

Our committee is unable to recommend lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease. Benefits of slowing disease progression, by 4-6 months on average, can not justify the high cost to the NHS. Learn more: nice.org.uk/news/articles/…

📢Our new paper out: Are glucagon-like peptide-1 receptor agonists #semaglutide and #liraglutide associated with disproportionately increased reporting of #suicidality? Disproportionality Analysis From WHO data 👇 jamanetwork.com/journals/jaman… Georgios Schoretsanitis Epidemiology and Psychiatry Verona #Ozempic

One really wonders how given such rapid and sustained effects ketamine is not yet approved, let alone first-line treatment for depression. At least make the title "locking away depression in mice", to make it clear this major public health problem of the mouse world is fixed.

If you want to make a dent into rates of mental health problems, make sure people have a roof over their heads, health insurance coverage, enough food to eat. Let's start there. And let's not forget Kendler: "You would not explain hypertension at the level of quarks".

We are concerned that the effects of the intervention in the Swiss TrAumatic biRth Trial (START) were exaggerated, owing to issues of selective reporting, lack of multiplicity corrections in the statistical analyses and to interpretive bias or “spin”. rdcu.be/dL57B

🗞️ Just out: ‘The papers that most heavily cite retracted studies’ by Miryam Naddaf Richard Van Noorden nature.com/articles/d4158…, a companion paper to my Comment: ‘Chain retraction: how to stop bad science propagating through the literature’ nature.com/articles/d4158… feat. PPS Feet of Clay.

“They knock on our door and we don’t see them” - incredibly interesting talk from Merete Nordentoft on crucial elements in national suicide prevention action plans and how to translate epidemiological evidence to action #ESSSB20

Robin Carhart-Harris Isn’t it just that the shoe is on the other foot now?

Hope to see you both soon!

EEG may be best placed, but please show me the externally validated EEG biomarker (so validated on a new sample) to reliably predict...anything relevant in psychiatry. (If possible not with an interaction effect significant at p=0.04)

New paper just out in ⁦The BMJ⁩ : Navigating US participant data sharing requirements: implications for international clinical trials. Later, I will write a 🧵. bmj.com/content/386/bm…

🧵 on our recent The BMJ paper. Despite years of advocacy, data sharing in clinical trials isn’t the norm. But recent US policies could change this trend. #DataSharing #ClinicalTrials bmj.com/content/386/bm…